Intellia Therapeutics, Inc. (NTLA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
NTLA Revenue Analysis (2014–2025)
As of March 2, 2026, Intellia Therapeutics, Inc. (NTLA) generated trailing twelve-month (TTM) revenue of $0, reflecting significant decline in growth of -446.9% year-over-year. The most recent quarter (Q4 2025) recorded $-44,654,000 in revenue, down 424.0% sequentially.
Looking at the longer-term picture, NTLA's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $58.0 million in 2020.
When compared to Healthcare sector peers including ALNY (+65.2% YoY), IONS (+33.8% YoY), and ARWR (+4081.8% YoY), NTLA has underperformed the peer group in terms of revenue growth. Compare NTLA vs ALNY →
Peer Comparison
Compare NTLA's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| NTLACurrent | $0 | -446.9% | - | - | |
| ALNY | $3.7B | +65.2% | +49.8% | 13.5% | |
| IONS | $944M | +33.8% | +5.3% | -40.5% | |
| ARWR | $829M | +4081.8% | +56.6% | 11.9% | |
| CRSP | $4M | -81.7% | +37.3% | -18933.6% | |
| BEAM | $140M | +120.0% | +466.3% | -274.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $0 | -100.0% | $0 | - | $0 | - |
| 2024 | $57.9M | +59.6% | $47.6M | 82.2% | $-534,263,000 | -923.1% |
| 2023 | $36.3M | -30.4% | $27.3M | 75.3% | $-515,291,000 | -1420.5% |
| 2022 | $52.1M | +57.7% | $44.5M | 85.5% | $-458,164,000 | -879.0% |
| 2021 | $33.1M | -43.0% | $26.2M | 79.2% | $-267,850,000 | -810.4% |
| 2020 | $58.0M | +34.5% | $-92,414,000 | -159.4% | $-136,583,000 | -235.5% |
| 2019 | $43.1M | +41.6% | $-65,310,000 | -151.5% | $-106,368,000 | -246.8% |
| 2018 | $30.4M | +16.5% | $-58,681,000 | -192.8% | $-90,870,000 | -298.6% |
| 2017 | $26.1M | +58.5% | $-41,530,000 | -159.0% | $-69,555,000 | -266.3% |
| 2016 | $16.5M | +172.7% | $-15,361,000 | -93.2% | $-32,159,000 | -195.2% |
See NTLA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NTLA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare NTLA vs AGIO
See how NTLA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is NTLA's revenue growth accelerating or slowing?
NTLA revenue declined -446.9% year-over-year, contrasting with the 5-year CAGR of N/A. TTM revenue fell to $0.00. This reverses the prior growth trend.
What is NTLA's long-term revenue growth rate?
Intellia Therapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of -446.9% is below this long-term average.
How is NTLA's revenue distributed by segment?
NTLA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.